Holen Sie sich die Stockscreener-App
11.35
1.90%
-0.22
Handel nachbörslich:
11.45
0.10
+0.88%
Schlusskurs vom Vortag:
$11.57
Offen:
$11.6
24-Stunden-Volumen:
1.98M
Relative Volume:
0.48
Marktkapitalisierung:
$1.53B
Einnahmen:
-
Nettoeinkommen (Verlust:
$-191.97M
KGV:
-3.5946
EPS:
-3.1575
Netto-Cashflow:
$-159.63M
1W Leistung:
+0.80%
1M Leistung:
-19.79%
6M Leistung:
+69.66%
1J Leistung:
+160.92%
1-Tages-Spanne:
$11.20
$11.79
1-Wochen-Bereich:
$10.59
$11.79
52-Wochen-Spanne:
$3.97
$15.40
Compass Pathways Plc Adr Stock (CMPS) Company Profile
Firmenname
Compass Pathways Plc Adr
Sektor
Branche
Telefon
1-716-676-6461
Adresse
3RD FLOOR, 1 ASHLEY ROAD, CHESIRE
Compare CMPS vs HCA, THC, DVA, FMS, EHC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
CMPS
Compass Pathways Plc Adr
|
11.35 | 1.52B | 0 | -191.97M | -159.63M | -3.1575 |
HCA
Hca Healthcare Inc
|
402.58 | 86.43B | 76.39B | 7.81B | 7.93B | 29.08 |
THC
Tenet Healthcare Corp
|
254.84 | 20.96B | 21.46B | 2.65B | 3.35B | 19.23 |
DVA
Davita Inc
|
240.11 | 15.17B | 13.84B | 1.10B | 1.49B | 10.42 |
FMS
Fresenius Medical Care Ag Adr
|
25.67 | 13.36B | 22.44B | 1.35B | 2.03B | 1.9002 |
EHC
Encompass Health Corp
|
111.08 | 11.30B | 6.07B | 793.80M | 464.40M | 5.9914 |
Compass Pathways Plc Adr Stock (CMPS) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-04-24 | Eingeleitet | B. Riley Securities | Buy |
| 2025-12-10 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2025-06-23 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2025-02-27 | Eingeleitet | Stifel | Buy |
| 2024-07-23 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2024-04-01 | Eingeleitet | Morgan Stanley | Overweight |
| 2023-12-12 | Eingeleitet | Deutsche Bank | Buy |
| 2022-11-21 | Fortgesetzt | Berenberg | Buy |
| 2022-11-01 | Eingeleitet | Loop Capital | Buy |
| 2021-10-29 | Eingeleitet | Oppenheimer | Outperform |
| 2021-07-13 | Eingeleitet | Citigroup | Buy |
| 2021-06-28 | Eingeleitet | Maxim Group | Buy |
| 2021-05-11 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2021-04-01 | Eingeleitet | ROTH Capital | Buy |
| 2020-10-14 | Eingeleitet | H.C. Wainwright | Buy |
| 2020-10-13 | Eingeleitet | Berenberg | Buy |
| 2020-10-13 | Eingeleitet | Canaccord Genuity | Buy |
| 2020-10-13 | Eingeleitet | Cowen | Outperform |
| 2020-10-13 | Eingeleitet | Evercore ISI | Outperform |
Alle ansehen
Compass Pathways Plc Adr Aktie (CMPS) Neueste Nachrichten
CMPS Stock Quote Price and Forecast - CNN
COMPASS Pathways plc (CMPS) Stock Price, News, Quote & History - Yahoo! Finance Canada
A Depression Drug Just Cleared a Key Hurdle Early, and the Market for New Mental Health Treatments Keeps Widening - Sahm
Why Is Neuronetics Stock Soaring Monday? - Sahm
AtaiBeckley surges after report Lilly poised to buy psychedelic drug developer - Sahm
Big Pharma Just Paid Up to $3.8 Billion for Psychedelic Medicine, and the Rest of the Sector Is Being Repriced in Real Time - Sahm
Compass Pathways study shows minimal interaction in psilocybin trials By Investing.com - Investing.com South Africa
Compass Pathways study shows minimal interaction in psilocybin trials - Investing.com
Should COMP360’s Durable Phase 3 Results and FDA Momentum Require Action From COMPASS Pathways (CMPS) Investors? - Sahm
Compass Pathways Eyes 2027 Launch as Psilocybin Depression Data Holds Up - Yahoo Finance
Compass Pathways stock falls on Phase 3 trial data release By Investing.com - Investing.com South Africa
Compass Pathways stock falls on Phase 3 trial data release - Investing.com
Compass Pathways reports 6-month data from phase 3 TRD trial - Investing.com
Why is Compass Pathways stock gaining today? By Investing.com - Investing.com South Africa
Why is Compass Pathways stock gaining today? - Investing.com
Is AtaiBeckley Stock Worth Buying After Its Stronger Rally in 2026? - TradingView
AtaiBeckley Stock Outlook Depends on Key Pipeline Catalysts in 2026 - TradingView
Enterprise value to EBIT forward of COMPASS Pathways Plc Sponsored ADR – MUN:5Y6 - TradingView
Compass Pathways stock hits 52-week high at 14.77 USD By Investing.com - Investing.com South Africa
Compass Pathways stock hits 52-week high at 14.77 USD - Investing.com
COMPASS Pathways Plc Sponsored ADR Actuals & Estimates (NASDAQ:CMPS) - TradingView
Why is Compass Pathways stock being clobbered today? - Investing.com
Compass Pathways earnings on deck as psychedelic approval nears - Investing.com
Why is Compass Pathways stock surging 9% today? By Investing.com - Investing.com India
Why is Compass Pathways stock surging 9% today? - Investing.com
Compass Pathways stock hits 52-week high at 12.48 USD By Investing.com - Investing.com South Africa
Compass Pathways stock hits 52-week high at 12.48 USD - Investing.com
Compass Pathways elects Kathleen Tregoning to board By Investing.com - Investing.com South Africa
Compass Pathways elects Kathleen Tregoning to board - Investing.com
CMPSCompass Pathways Plc ADR Stock Price and Quote - Finviz
COMPASS Pathways Plc Q1 2026 Earnings: Narrower Loss Provides Hope Amid Pre-Revenue StageLow Growth Earnings - Newser
Wolfe Research initiates Compass Pathways stock with outperform rating - Investing.com
Compass Pathways stock hits 52-week high at 11.65 USD - Investing.com
Compass Pathways stock hits 52-week high at 11.65 USD By Investing.com - Investing.com India
Compass Pathways Eyes Q4 FDA Filing for Psilocybin Depression Drug After Phase 3 Wins - Yahoo Finance
Why LiveRamp Shares Are Trading Higher By Over 26%; Here Are 20 Stocks Moving Premarket - Sahm
Is Compass Pathways (CMPS) outperforming other medical stocks this year? - MSN
Compass Pathways Reports Strong Q1 Results, Shares Surge - Sahm
Why COMPASS Pathways (CMPS) Is Up 13.1% After FDA Fast-Track Moves For COMP360 Profit Shift - Sahm
Compass Pathways stock hits 52-week high at 10.22 USD - Investing.com India
Compass Pathways Q1 Earnings Call Highlights - Barchart.com
Compass Pathways stock surges 8% on beating estimates as FDA accelerates review - Investing.com India
Compass Pathways stock surges 8% on beating estimates as FDA accelerates review By Investing.com - Investing.com South Africa
Finanzdaten der Compass Pathways Plc Adr-Aktie (CMPS)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.03%
0.48%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):